Precision medicine is entering a new phase of growth, expanding beyond its traditional stronghold in oncology and into new therapeutic areas such as neurodegenerative disorders. In a recent thought-leadership interview, Miro Venturi, President and CEO of Diamante Healthcare Consulting, discussed the strategic challenges facing healthcare and life sciences companies, and what will determine success as innovation moves closer to the market.
Venturi noted that precision medicine has made significant progress in recent years, with biomarkers and diagnostics increasingly supporting access to novel therapies. While oncology has long been the central focus, new applications are emerging in areas where diagnostic strategies can help identify the right patients and strengthen the case for market access.
However, the sector is still facing headwinds. Venturi pointed to a softer market environment, particularly around commitment and investment in emerging companies developing assets with a strong precision medicine component. He suggested that the second half of 2026 may bring renewed momentum, with further market development and increased investor engagement.
For early-stage companies, navigating reimbursement, market access and commercialization remains a major challenge. This is where consulting can play a critical role. Venturi explained that Diamante Healthcare Consulting focuses on helping entrepreneurs and scientists translate innovation into commercially viable strategies. Rather than interfering with the underlying science, the firm supports companies in areas such as reimbursement planning, market access, diagnostic strategy and commercialization readiness.
Partnerships are also essential to successful commercialization. Venturi emphasized that no single company can deliver every element required for precision medicine adoption. Pharma companies need to collaborate with diagnostics and med tech partners that understand installed equipment bases, regulatory pathways and testing workflows. They must also work with payers, reimbursement bodies and healthcare agencies to ensure innovation is appropriately valued and adopted.
Looking ahead, Venturi sees value-based healthcare as one of the most important trends shaping the next five years. While AI will continue to act as an enabler and accelerator, he argued that the central challenge will be ensuring that therapeutic and diagnostic innovation delivers recognized value for patients, healthcare systems and other stakeholders.
For companies bringing healthcare innovation to market, Venturi believes success depends on keeping the end goal in mind from the beginning. Strong science is essential, but it must evolve into a product that addresses real market gaps and can be adopted by customers, including patients, physicians, laboratories and payers. The companies that succeed will be those that remain closely aligned with customer needs, market fit and the practical realities of healthcare adoption.
